NRAS and melanoma: Thus, binimetinib was not approved for the treatment of metastatic melanoma patients with Nras mutations but it is included in National Comprehensive Cancer Network (NCCN) guidelines as an option for patients that have failed immunotherapy.26 A number of KIT inhibitors that are approved in other diseases with Kit mutations have also been evaluated in melanoma.